Ph染色体阴性骨髓增殖性肿瘤加速期/急变期患者的临床特征及预后因素分析
回顾性分析2014年2月至2021年12月中国医学科学院血液病医院67例Ph染色体阴性MPN-AP/BP患者,中位年龄60岁。PMF进展组脾肿大、骨髓网状纤维≥2级比例更高,LDH更高,进展时间更短。复杂染色体核型是OS独立不良预后因素,allo-HSCT和白血病样化疗较支持治疗延长OS。
要点
- PMF进展的MPN-AP/BP患者脾肿大比例81.4%、骨髓网状纤维≥2级93.6%,均高于其他MPN进展组。
- 复杂染色体核型是OS独立不良预后因素(HR=2.53,95%CI 1.06~6.05,P=0.036)。
- allo-HSCT和白血病样化疗较支持治疗延长OS,中位OS分别为21.3个月和13.0个月对3.0个月。
核心结论
- PMF进展的MPN-AP/BP患者较其他Ph染色体阴性MPN-AP/BP患者脾肿大和骨髓网状纤维≥2级发生率更高、LDH水平更高、进展为AP/BP时间更短。
- 复杂染色体核型是影响MPN-AP/BP患者OS的独立不良预后因素。
- 与支持治疗相比,白血病样化疗和allo-HSCT可延长MPN-AP/BP患者OS。
研究设计与样本
- 回顾性分析2014年2月至2021年12月中国医学科学院血液病医院67例Ph染色体阴性MPN-AP/BP患者的病例资料。
- 67例中男31例(46.3%),女36例(53.7%),中位年龄60(33~75)岁。
- PMF进展48例(PMF-AP/BP组),PV、ET、MPN-U进展19例(其他MPN-AP/BP组)。
主要发现
- PMF-AP/BP组较其他MPN-AP/BP组LDH更高(925.9 U/L对576.2 U/L,P=0.011)。
- PMF-AP/BP组较其他MPN-AP/BP组脾肿大比例更高(81.4%对57.9%,P=0.05),骨髓网状纤维≥2级比例更高(93.6%对63.2%,P=0.004)。
- PMF-AP/BP组较其他MPN-AP/BP组进展为AP/BP时间更短(28.7个月对81.0个月,P=0.001)。
- PMF-AP/BP组较其他MPN-AP/BP组ASXL1突变检出率更高(51.1%对21.1%,P=0.03),SRSF2突变VAF更高(48.8%对39.6%,P=0.008)。
- allo-HSCT组中位OS 21.3个月(95%CI 10.2~32.3)对支持治疗组3.0个月(95%CI 2.3~3.7),P=0.05;白血病样化疗组中位OS 13.0个月(95%CI 8.3~17.7)对支持治疗组3.0个月(95%CI 2.3~3.7),P=0.011。
关键数值与推荐
- 复杂染色体核型与更差OS独立相关(HR=2.53,95%CI 1.06~6.05,P=0.036)。
- JAK2V617F检出41例(61.2%),CALR外显子9突变13例(19.4%),MPLW515突变3例(4.5%),三阴性10例(14.9%)。
- 非驱动基因突变检出率:ASXL1 42.2%(27例)、SRSF2 25.0%(16例)、SETBP1 22.6%(15例)、TET2 20.3%(13例)、RUNX1 20.3%(13例)、TP53 17.2%(11例)。
临床怎么用
- 原文结论指出,与支持治疗相比,白血病样化疗和allo-HSCT可延长MPN-AP/BP患者OS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm-accelerated phase/blast phase (MPN-AP/BP) . Methods: A total of 67 patients with MPN-AP/BP were enrolled from February 2014 to December 2021 at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. Their clinical features and prognostic factors were analyzed retrospectively. Results: ① Sixty-seven patients with MPN-AP/BP with a median age of 60 (range, 33-75) years, including 31 males (46.3% ) and 36 females (53.7% ) , were analyzed. Forty-eight patients progressed from primary myelofibrosis (PMF) , and 19 progressed from other myeloproliferative neoplasms (MPNs) , which included polycythemia vera, essential thrombocythemia, and MPN unclassifiable. Patients who progressed from PMF had higher lactate dehydrogenase (LDH) levels than those who progressed from other MPNs (925.95 vs. 576.2 U/L, P=0.011) , and there were higher proportions of patients who progressed from PMF with splenomegaly (81.4% vs. 57.9% , P=0.05) , a myelofibrosis grade of ≥2 (93.6% vs. 63.2% , P=0.004) , and a shorter duration from diagnosis to the transformation to AP/BP (28.7 vs. 81 months, P=0.001) . ② JAK2V617F, CALR, and MPLW515 were detected in 41 (61.2% ) , 13 (19.4% ) , and 3 (4.5% ) patients, respectively, whereas 10 (14.9% ) patients did not have any driver mutations (triple-negative) . Other than driver mutations, the most frequently mutated genes were ASXL1 (42.2% , n=27) , SRSF2 (25% , n=16) , SETBP1 (22.6% , n=15) , TET2 (20.3% , n=13) , RUNX1 (20.3% , n=13) , and TP53 (17.2% , n=11) . The ASXL1 mutation was more enriched (51.1% vs. 21.1% , P=0.03) , and the median variant allele fraction (VAF) of the SRSF2 mutation (median VAF, 48.8% vs. 39.6% ; P=0.008) was higher in patients who progressed from PMF than those who progressed from other MPNs. ③ In the multivariate analysis, the complex karyotype (hazard ratio, 2.53; 95% confidence interval, 1.06-6.05; P=0.036) was independently associated with worse overall survival (OS) . Patients who received allogeneic stem cell transplantation (allo-HSCT) (median OS, 21.3 vs. 3 months; P=0.05) or acute myeloid leukemia-like (AML-like) therapy (median OS, 13 vs. 3 months; P=0.011) had significantly better OS than those who received supportive therapy. Conclusion: The proportions of patients with PMF-AP/BP with splenomegaly, myelofibrosis grade ≥2, a higher LDH level, and a shorter duration from diagnosis to the transformation to AP/BP were higher than those of patients with other Philadelphia-negative MPN-AP/BP. The complex karyotype was an independent prognostic factor for OS. Compared with supportive therapy, AML-like therapy and allo-HSCT could prolong the OS of patients with MPN-AP/BP. 目的: 分析Ph染色体阴性骨髓增殖性肿瘤加速期/急变期(MPN-AP/BP)患者的临床特征及预后因素。 方法: 收集2014年2月至2021年12月期间就诊于中国医学科学院血液病医院的67例Ph染色体阴性MPN-AP/BP患者的病例资料,回顾性分析其临床特征及预后因素。 结果: ①全部67例MPN-AP/BP患者中男31例(46.3%),女36例(53.7%),中位年龄为60(33~75)岁;原发性骨髓纤维化(PMF)进展的患者48例(PMF-AP/BP组),由真性红细胞增多症(PV)、原发性血小板增多症(ET)、骨髓增殖性肿瘤不能分类(MPN-U)进展的患者19例(其他MPN-AP/BP组)。PMF-AP/BP组与其他MPN-AP/BP组比较,乳酸脱氢酶(LDH)水平较高(925.9 U/L对576.2 U/L,P=0.011),脾肿大患者占比较高(81.4%对57.9%,P=0.05),骨髓网状纤维≥2级者占比较高(93.6%对63.2%,P=0.004),进展为AP/BP时间较短(28.7个月对81.0个月,P=0.001)。②67例Ph染色体阴性MPN-AP/BP患者中,41例(61.2%)检出JAK2V617F突变,13例(19.4%)检出CALR外显子9突变(1型CALR突变11例,2型CALR突变2例),3例(4.5%)检出MPLW515突变,JAK2、MPL和CALR基因突变均未检出10例(14.9%);非驱动基因突变检出率较高的依次为ASXL1(42.2%,27例)、SRSF2(25.0%,16例)、SETBP1(22.6%,15例)、TET2(20.3%,13例)、RUNX1(20.3%,13例)和TP53基因(17.2%,11例)。PMF-AP/BP组ASXL1基因突变检出率(51.1%对21.1%,P=0.03)及SRSF2基因突变频率(VAF)高于其他MPN-AP/BP组(48.8%对39.6%,P=0.008)。③多因素分析示复杂染色体核型是影响MPN-AP/BP患者总生存(OS)期的独立不良预后因素(HR=2.53,95%CI 1.06~6.05,P=0.036)。接受异基因造血干细胞移植或白血病样化疗的患者与接受支持治疗的患者比较,OS期较长[(21.3(95%CI 10.2~32.3)个月对3.0(95%CI 2.3~3.7)个月,P=0.05;13.0(95%CI 8.3~17.7)个月对3.0(95%CI 2.3~3.7)个月,P=0.011]。 结论: 与其他Ph染色体阴性MPN-AP/BP患者比较,PMF-AP/BP患者具有较高的脾肿大和骨髓网状纤维≥2级发生率、较高的LDH水平,进展为AP/BP时间也较短。复杂染色体核型是影响MPN-AP/BP患者OS期的独立不良预后因素。异基因造血干细胞移植和白血病样化疗可延长MPN-AP/BP患者OS期。.
引用
- Yan X, Qin TJ, Li B, et al. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37356995. doi:10.3760/cma.j.issn.0253-2727.2023.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。